COYA — Coya Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $97.82m
- $50.99m
- $7.95m
Annual income statement for Coya Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 6 | 3.55 | 7.95 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.87 | 9.81 | 13.9 | 20.8 | 30.5 |
| Operating Profit | -4.87 | -9.81 | -7.9 | -17.2 | -22.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.89 | -12.2 | -7.26 | -15.6 | -21.2 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -4.89 | -12.2 | -7.99 | -14.9 | -21.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.89 | -12.2 | -7.99 | -14.9 | -21.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.89 | -12.2 | -7.99 | -14.9 | -21.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.507 | -1.23 | -0.732 | -0.975 | -1.13 |
| Dividends per Share |